Trilaciclib Dihydrochloride

The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026 BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company, today announced that an abstract for SIM0505 has been accepted for the American Society for Clinical Oncology (ASCO 2026) meeting being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ongoing open-label, Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. About SIM0505 SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd. About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response. About Simcere Zaiming Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu®, COSELA®, Enweida®, Endostar®, and Enlituo®. The Company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners. Forward-Looking Statements Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “should”, “due”, “estimate”, “expect”, “intend”, “hope”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “seek”, “target”, “towards”, “forward”, “later”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: market and other conditions; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s reliance upon collaborators and international vendors for advancing clinical programs; NextCure’s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change. Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 IR@nextcure.com Mike Moyer Managing Director, LifeSci Advisors, LLC Phone: (617) 308-4306 mmoyer@lifesciadvisors.com Source: NextCure

3月25日，先声药业（02096.HK）正式官宣重磅人事任命：周云曙获委任为公司首席执行官（CEO），全面统筹集团运营管理；创始人任晋生卸任CEO，继续担任董事长兼执行董事，专注长期战略与重大决策。此次换帅，标志着先声药业迈入“战略掌舵+运营执行”的专业化治理新阶段，也为公司创新战略2.0注入强劲动能。 老将出山：30年医药履历，执掌创新药企 周云曙现年54岁，是医药界公认的全能型老将，拥有超30年行业经验。 - 恒瑞26年深耕：1995年加入恒瑞医药前身，从基层起步，历任发展部部长、副总经理、总经理，2020年出任董事长，深度主导恒瑞从仿制药向创新药龙头的转型，搭建全球研发体系，推动多款重磅创新药落地。 - 信达顾问历练：2022-2025年任信达生物全职顾问，聚焦创新药市场策略与商业化体系搭建，补齐生物药运营经验。 - 先声快速晋升：2025年12月以总裁身份亮相，3个月后正式出任CEO，年薪600万港元+绩效花红，彰显公司对其能力的高度认可。 先声底气：创新驱动，业绩稳健增长 此次人事调整，恰逢先声药业2025年业绩亮眼收官，为新CEO履职奠定坚实基础。 - 业绩表现：2025年营收77.31亿元，同比+16.5%；创新药收入63.04亿元，同比+27.9%，占比达81.5%，成为核心增长引擎。 - 管线实力：拥有10款商业化创新药，研发管线超60项，覆盖小分子、单抗、双抗、ADC等前沿技术；2款新药NDA审评中，6款进入III期临床，13款推进至早期临床。 - 战略布局：推进创新战略2.0，聚焦神经科学、肿瘤等核心领域，加速全球化拓展；启动“全重求索计划”，5年投入20亿元支持颠覆性创新。 新程启航：周云曙发布“双30”目标，剑指200亿营收 履新首日，周云曙在业绩会上正式发布先声药业2026-2030年战略目标： - 2026年“双30”目标：营收同比+30%，突破100亿元；经调整净利润同比+30%，达16亿元。 - 2030年展望：营收突破200亿元，经调整净利润超30亿元，研发投入超40亿元。 - 增长引擎：核心产品先必新系列、科唯可、科赛拉等，叠加对外授权收入，支撑业绩高增。 行业意义：专业化治理升级，赋能创新药发展 先声药业此次换帅，是国内创新药企治理结构优化的典型案例。 - 治理升级：从创始人主导迈向职业经理人专业化管理，形成“董事长定战略、CEO抓执行”的高效分工。 - 能力互补：周云曙在研发、商业化、全球化运营的全链条经验，将补齐先声规模化放量、渠道深耕与海外拓展短板。 - 行业影响：头部药企老将加盟，将加速先声创新药商业化进程，提升行业竞争力，为中国创新药发展注入新活力。 从恒瑞到信达，再到先声，周云曙的每一步都紧扣中国医药创新浪潮。此次执掌先声药业，既是对其过往成绩的认可，更是对先声未来的期许。在创新战略2.0指引下，凭借周云曙的操盘能力与先声的管线实力，公司有望加速实现百亿营收目标，迈向全球一流创新药企之列。